Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
003000.KS
Top 10 Correlated ETFs
003000.KS
Top 10 Correlated Stocks
003000.KS
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 2.42K | 3.49K | 2.46K | 2.72K | 1.74K | |
| Net income per share | 177.74 | 2.61K | -108.5 | -115.45 | -8.74 | |
| Operating cash flow per share | 137.23 | 122.32 | -342.64 | 11.59 | 252.86 | |
| Free cash flow per share | 32.61 | 55.45 | -414.45 | -19.73 | 245.34 | |
| Cash per share | 387.17 | 1.8K | 550.17 | 1.44K | 803.41 | |
| Book value per share | 3.39K | 7.42K | 4.78K | 4.14K | 2.57K | |
| Tangible book value per share | 3.17K | 7.26K | 4.63K | 4.23K | 2.6K | |
| Share holders equity per share | 3.39K | 7.42K | 4.78K | 4.14K | 2.57K | |
| Interest debt per share | 0 | 0 | 31.75 | 369.63 | 28.28 | |
| Market cap | 1184.35B | 1097.7B | 869.46B | 1397.55B | 1111.93B | |
| Enterprise value | 1160.2B | 997.3B | 833.96B | 1339.81B | 1030.71B | |
| P/E ratio | 106.79 | 7.54 | -117.3 | -194.02 | -1.21K | |
| Price to sales ratio | 7.86 | 5.65 | 5.17 | 8.24 | 6.09 | |
| POCF ratio | 138.32 | 161.03 | -37.14 | 1.93K | 41.92 | |
| PFCF ratio | 582.07 | 355.23 | -30.71 | -1.14K | 43.21 | |
| P/B Ratio | 5.61 | 2.66 | 2.67 | 5.41 | 4.12 | |
| PTB ratio | 5.61 | 2.66 | 2.67 | 5.41 | 4.12 | |
| EV to sales | 7.7 | 5.13 | 4.96 | 7.9 | 5.65 | |
| Enterprise value over EBITDA | 55.29 | 5.04 | 181.64 | 589.06 | 86.48 | |
| EV to operating cash flow | 135.5 | 146.3 | -35.63 | 1.85K | 38.86 | |
| EV to free cash flow | 570.19 | 322.74 | -29.45 | -1.09K | 40.05 | |
| Earnings yield | 0.01 | 0.13 | -0.01 | -0.01 | 0 | |
| Free cash flow yield | 0 | 0 | -0.03 | 0 | 0.02 | |
| Debt to equity | 0 | 0 | 0.01 | 0 | 0 | |
| Debt to assets | 0.11 | 0.16 | 0.16 | 0.32 | 0.3 | |
| Net debt to EBITDA | -1.15 | -0.51 | -7.73 | -25.39 | -6.81 | |
| Current ratio | 6.46 | 5.79 | 5.19 | 4.06 | 5.95 | |
| Interest coverage | 0 | 0 | 104.98 | 2.66 | 3.99 | |
| Income quality | 0.77 | 0.05 | 3.16 | -0.1 | -28.94 | |
| Dividend Yield | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 1.62 | 0.06 | -1.32 | -1.69 | -6.79 | |
| Sales general and administrative to revenue | 0.04 | 0.04 | 0.04 | 0.03 | 0.02 | |
| Research and developement to revenue | 0.17 | 0.13 | 0.1 | 0.11 | 0.12 | |
| Intangibles to total assets | 0.06 | 0.02 | 0.03 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.76 | -0.55 | 0.21 | -2.7 | -0.03 | |
| Capex to revenue | -0.04 | -0.02 | -0.03 | -0.01 | 0 | |
| Capex to depreciation | -1.07 | -0.54 | -0.84 | -0.32 | -0.16 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.02 | 0 | |
| Graham number | 3.68K | 20.89K | 3.41K | 3.28K | 710.86 | |
| ROIC | 0.04 | 0.08 | 0.03 | 0.01 | 0.02 | |
| Return on tangible assets | 0.05 | 0.3 | -0.02 | -0.02 | 0 | |
| Graham Net | 305.12 | 669.96 | -35.06 | -232.4 | -128.04 | |
| Working capital | 105.08B | 183.39B | 150.51B | 187B | 183.1B | |
| Tangible asset value | 198B | 404.47B | 316.1B | 264.19B | 273.08B | |
| Net current asset value | 99.4B | 141.46B | 124.35B | 118.43B | 102.74B | |
| Invested capital | 0 | 0 | 0.01 | 0.08 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 7.42B | 7.25B | 10.02B | 10.16B | 8.79B | |
| Average inventory | 45.49B | 42.8B | 47.76B | 51.37B | 45.33B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 24.37 | 20 | 43 | 37.82 | 25.38 | |
| Days of inventory on hand | 206.22 | 157.67 | 191.91 | 191.31 | 134.38 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 14.97 | 18.25 | 8.49 | 9.65 | 14.38 | |
| Inventory turnover | 1.77 | 2.31 | 1.9 | 1.91 | 2.72 | |
| ROE | 0.05 | 0.35 | -0.02 | -0.03 | 0 | |
| Capex per share | -104.62 | -66.87 | -71.81 | -31.32 | -7.53 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 658.37 | 717.8 | 1.72K | 1.17K | 610.38 | |
| Net income per share | -4 | 9.87 | 60.75 | -67.48 | -6 | |
| Operating cash flow per share | -109.63 | 284.7 | 304.01 | 453.59 | -62.01 | |
| Free cash flow per share | -111.2 | 278.7 | 301.04 | 446 | -70.87 | |
| Cash per share | 1.24K | 0 | 2.68K | 0 | 1.25K | |
| Book value per share | 3.72K | 3.74K | 8.58K | 8.28K | 3.72K | |
| Tangible book value per share | 3.8K | 3.92K | 8.69K | 8.59K | 3.75K | |
| Share holders equity per share | 3.72K | 3.74K | 8.58K | 8.28K | 3.72K | |
| Interest debt per share | 326.45 | 0 | 49.6 | 1.67 | 27.96 | |
| Market cap | 1349.2B | 999.41B | 405.33B | 400.62B | 594.17B | |
| Enterprise value | 1288.51B | 999.41B | 324.11B | 400.62B | 509.71B | |
| P/E ratio | -1.27K | 380.05 | 53.08 | -47.23 | -352.5 | |
| Price to sales ratio | 30.76 | 20.9 | 7.51 | 10.85 | 13.86 | |
| POCF ratio | -184.71 | 52.69 | 42.43 | 28.11 | -136.43 | |
| PFCF ratio | -182.1 | 53.82 | 42.85 | 28.59 | -119.38 | |
| P/B Ratio | 5.44 | 4.01 | 1.5 | 1.54 | 2.28 | |
| PTB ratio | 5.44 | 4.01 | 1.5 | 1.54 | 2.28 | |
| EV to sales | 29.37 | 20.9 | 6.01 | 10.85 | 11.89 | |
| Enterprise value over EBITDA | 9.03K | 302.69 | 46.7 | -557.89 | 210.41 | |
| EV to operating cash flow | -176.4 | 52.69 | 33.93 | 28.11 | -117.04 | |
| EV to free cash flow | -173.91 | 53.82 | 34.26 | 28.59 | -102.41 | |
| Earnings yield | 0 | 0 | 0 | -0.01 | 0 | |
| Free cash flow yield | -0.01 | 0.02 | 0.02 | 0.03 | -0.01 | |
| Debt to equity | 0.01 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.32 | 0.29 | 0.3 | 0.31 | 0.3 | |
| Net debt to EBITDA | -425.11 | 0 | -11.7 | 0 | -34.87 | |
| Current ratio | 4.39 | 6.67 | 5.95 | 5.2 | 6.06 | |
| Interest coverage | 0 | 0 | 0 | -37.8 | -0.79 | |
| Income quality | 27.41 | 28.85 | 5 | -6.72 | 10.33 | |
| Dividend Yield | 0 | 0 | 0 | 0.02 | 0 | |
| Payout ratio | 0 | 0 | 0 | -3.23 | 0 | |
| Sales general and administrative to revenue | 0.26 | 0.35 | 0.02 | 0.48 | 0.3 | |
| Research and developement to revenue | 0.13 | 0 | 0.1 | 0 | 0.15 | |
| Intangibles to total assets | 0.02 | 0 | 0.02 | 0 | 0.02 | |
| Capex to operating cash flow | 0.01 | -0.02 | -0.01 | -0.02 | 0.14 | |
| Capex to revenue | 0 | -0.01 | 0 | -0.01 | -0.01 | |
| Capex to depreciation | -0.08 | -0.33 | -0.08 | -0.22 | -0.57 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 578.9 | 911.54 | 3.42K | 3.55K | 708.2 | |
| ROIC | 0 | 0.06 | 0.01 | -0.01 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | -0.01 | 0 | |
| Graham Net | -225.68 | -1.58K | -427.46 | -3.89K | -79.47 | |
| Working capital | 182.82B | 186.09B | 183.1B | 174.85B | 177.2B | |
| Tangible asset value | 252.87B | 0 | 273.08B | 0 | 263.39B | |
| Net current asset value | 112.66B | 113.83B | 102.74B | 94.22B | 96.83B | |
| Invested capital | 0.09 | 0 | 0.01 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 37.44 | 0 | 21.1 | 0 | 40.68 | |
| Days of inventory on hand | 176.36 | 0 | 111.75 | 0 | 164.94 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.4 | 0 | 4.26 | 0 | 2.21 | |
| Inventory turnover | 0.51 | 0 | 0.81 | 0 | 0.55 | |
| ROE | 0 | 0 | 0.01 | -0.01 | 0 | |
| Capex per share | -1.57 | -6 | -2.97 | -7.59 | -8.86 |
Frequently Asked Questions
What is Bukwang Pharmaceutical Co., Ltd. stock symbol ?
Bukwang Pharmaceutical Co., Ltd. is a US stock and trading under the symbol 003000.KS
What is Bukwang Pharmaceutical Co., Ltd. stock quote today ?
Bukwang Pharmaceutical Co., Ltd. stock price is $7610 today.
Is Bukwang Pharmaceutical Co., Ltd. stock public?
Yes, Bukwang Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 774.79K
- Market Capitalization 567.49B
- Employee 571
- Headquarters Seoul,US
- IPO Date 2005-09-29
-
Website
https://www.bukwang.co.kr 
Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
